Evidence map›Paper›PMID 26460950›Full record

ArticleOncotarget2015

Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.

You-Jun Li, Guodong Liu, Lei Xia, Xiao Xiao, Jeff C Liu, Mitchell E Menezes, Swadesh K Das, Luni Emdad, Devanand Sarkar, Paul B Fisher and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

You-Jun LiDepartment of Anatomy, Norman Bethune College of Medicine, Jilin University, Changchun, Jilin, China.
Guodong LiuDepartment of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
Lei XiaDivision of Biology, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, China.
Xiao XiaoDivision of Biology, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, China.
Jeff C LiuToronto General Research Institute - University Health Network, Toronto, Ontario, Canada.
Mitchell E MenezesDepartment of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Swadesh K DasDepartment of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Luni EmdadDepartment of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Devanand SarkarDepartment of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Paul B FisherDepartment of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Michael C ArcherDepartment of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
Eldad ZacksenhausDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Yaacov Ben-DavidDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Virginia Commonwealth University · USKey Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences · CNUniversity Health Network · CAUniversity of Toronto · CAFirst Bethune Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) encodes a tumor suppressor gene implicated in the growth of various tumor types including breast cancer. We previously demonstrated that recombinant adenovirus-mediated mda-7/IL-24 expression in the mammary glands of carcinogen-treated (methylnitrosourea, MNU) rats suppressed mammary tumor development. Since most MNU-induced tumors in rats contain activating mutations in Ha-ras, which arenot frequently detected in humans, we presently examined the effect of MDA-7/IL-24 on Her2/Neu-induced mammary tumors, in which the RAS pathway is induced. We generated tet-inducible MDA-7/IL-24 transgenic mice and crossed them with Her2/Neu transgenic mice. Triple compound transgenic mice treated with doxycycline exhibited a strong inhibition of tumor development, demonstrating tumor suppressor activity by MDA-7/IL-24 in immune-competent mice. MDA-7/IL-24 induction also inhibited growth of tumors generated following injection of Her2/Neu tumor cells isolated from triple compound transgenic mice that had not been treated with doxycycline, into the mammary fat pads of isogenic FVB mice. Despite initial growth suppression, tumors in triple compound transgenic mice lost mda-7/IL-24 expression and grew, albeit after longer latency, indicating that continuous presence of this cytokine within tumor microenvironment is crucial to sustain tumor inhibitory activity. Mechanistically, MDA-7/IL-24 exerted its tumor suppression effect on HER2+ breast cancer cells, at least in part, through PERP, a member of PMP-22 family with growth arrest and apoptosis-inducing capacity. Overall, our results establish mda-7/IL-24 as a suppressor of mammary tumor development and provide a rationale for using this cytokine in the prevention/treatment of human breast cancer.

Indexed as

Disease Models, AnimalGene Expression Regulation, NeoplasticAnimalsApoptosisCell Transformation, NeoplasticErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoenzyme TechniquesInterleukin-24InterleukinsMammary Neoplasms, AnimalMammary Tumor Virus, MouseMembrane ProteinsMiceMice, TransgenicErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesInterleukin-24InterleukinsMembrane ProteinsPerp protein, mouseRNA, Messengerbreast cancerHER2mda-7/IL-24mouse modelprevention

Identifiers

PMID26460950
PMCPMC4741907
OpenAlexW2175083747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.